Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC. A 73-year-old Japanese man diagnosed with a large HCC was treated with atezolizumab plus bevacizumab. After 2 cycles, he had fever and fatigue and was admitted to the hospital. Abdominal contrast-enhanced computed tomography revealed tumor necrosis in HCC with gas formation in the necrotic area. Laboratory examination revealed a white blood cell (WBC) count of 16,340/μL and C-reactive protein (CRP) level of 33.0 mg/dL. Based on the above findings, he was diagnosed with a liver abscess. Percutaneous transhepatic liver abscess drainage and broad-spectrum antibiotics treatment were performed. Despite liver abscess drainage, persistent fever and no improvement in the WBC count or CRP level was observed. The patient's respiratory condition and renal function gradually worsened; The patient's general condition did not improve despite the ventilator support and continuous hemodiafiltration, and he died on day 37. We report the first case of liver abscess after atezolizumab plus bevacizumab treatment for unresectable HCC.
Identifiants
pubmed: 36107543
doi: 10.1097/MD.0000000000030486
pii: 00005792-202209020-00107
pmc: PMC9439774
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antibodies, Monoclonal, Humanized
0
Bevacizumab
2S9ZZM9Q9V
atezolizumab
52CMI0WC3Y
C-Reactive Protein
9007-41-4
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30486Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
There are no funding or conflicts of interest to disclose.
Références
Frontline Gastroenterol. 2014 Jan;5(1):60-67
pubmed: 28839753
J Clin Oncol. 2008 Mar 10;26(8):1381-2
pubmed: 18323561
Eur J Gastroenterol Hepatol. 2004 Aug;16(8):737-42
pubmed: 15256974
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
IDCases. 2020 Feb 28;20:e00736
pubmed: 32211296
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Surg Infect (Larchmt). 2021 May;22(4):427-433
pubmed: 32857017
Int J Syst Evol Microbiol. 2001 May;51(Pt 3):925-932
pubmed: 11411716
J Surg Case Rep. 2018 May 15;2018(5):rjy097
pubmed: 29780575
Ther Adv Med Oncol. 2020 May 26;12:1758835920927602
pubmed: 32518599
Int J Infect Dis. 2016 Apr;45:65-71
pubmed: 26921549
Am J Gastroenterol. 1993 Nov;88(11):1911-5
pubmed: 8237941
Cancer Manag Res. 2021 Sep 07;13:6935-6941
pubmed: 34522136
Ann Saudi Med. 2011 Jan-Feb;31(1):93-4
pubmed: 21245606
Radiology. 2003 Feb;226(2):441-51
pubmed: 12563138
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Surg Infect (Larchmt). 2020 Dec;21(10):884-890
pubmed: 32216699
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Ann Hepatobiliary Pancreat Surg. 2018 Feb;22(1):11-18
pubmed: 29536051
Korean J Gastroenterol. 2014 Jan 25;63(1):47-50
pubmed: 24463289
BMC Infect Dis. 2021 Sep 10;21(1):939
pubmed: 34507537